Tag : ASTHMA

In the NOVELTY study, higher baseline blood eosinophils (EOS) significantly predicted increased exacerbation risks in asthma and chronic obstructive pulmonary disease (COPD). Conversely, FeNO showed highly heterogeneous associations, paradoxically linking to a lower overall risk in COPD but increased odds of oral corticosteroid-treated exacerbations in asthma and asthma + COPD.

Malaysia’s 2024 Asthma Clinical Practice Guidelines (CPG) moves beyond short-acting β2-agonist (SABA)-only treatment, introducing inhaled corticosteroid (ICS)-based regimens from the earliest steps, phenotype/endotype-driven biologic algorithms, and system-level reforms to advance personalized asthma care

Severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) can significantly limit patients' activity levels. This post hoc analysis of the phase 3 NAVIGATOR study assessed the impact of tezepelumab on activity-related items within the Asthma Quality of Life Questionnaire

The anti-interleukin-5 receptor α (anti-IL-5α) monoclonal antibody (mAb), benralizumab, had been approved for the treatment of severe eosinophilic asthma offering significant improvements in exacerbation rates, maintenance oral corticosteroid (mOCS) use, and other asthma outcomes in phase 3 clinical trials. Although benralizumab has achieved asthma remission in clinical trials and non-United States (US) populations, real-world data within the US assessing similar outcomes remained limited.